Literature DB >> 1703351

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

T E Starzl1, K Abu-Elmagd, A Tzakis, J J Fung, K A Porter, S Todo.   

Abstract

FK 506 is a superior immunosuppressive agent that should improve the grafting of organs that already are part of our every day transplant practices, as well as those which are presently impractical. Immune intervention for serious autoimmune diseases also should be a more attractive option with this drug. Lessons are still being learned about dosage and what determines safe dose schedules. At a basic level, the study of FK 506 and its comparison to CyA may have shed light on mechanisms and characteristics of the whole class of so-called macrolide immunosuppresants and their cytosolic binding sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703351

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  37 in total

1.  History of clinical transplantation.

Authors:  T E Starzl
Journal:  World J Surg       Date:  2000-07       Impact factor: 3.352

Review 2.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

3.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

4.  Changes in renal function after liver transplantation under FK 506.

Authors:  J McCauley; J J Fung; S Todo; A Jain; P Deballi; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  Strategy of FK 506 therapy in liver transplant patients: effect of graft function.

Authors:  K M Abu-Elmagd; J J Fung; M Alessiani; A Jain; S Takaya; R Venkataramanan; V S Warty; W Shannon; S Todo; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome.

Authors:  J McCauley; R Shapiro; V Scantlebury; N Gilboa; M Jordan; C Jensen; A Naik; A Tzakis; D Ellis; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.

Authors:  K M Abu-Elmagd; J Fung; R Draviam; W Shannon; A Jain; M Alessiani; S Takaya; R Venkataramanan; V S Warty; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  Practical aspects of FK 506 analysis (Pittsburgh experience).

Authors:  V S Warty; R Venkataramanan; P Zendehrouh; S Mehta; T McKaveney; J Flowers; S Zuckerman; A Krajak; A Zeevi
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  Renal function after conversion from cyclosporine to FK 506 in liver transplant patients.

Authors:  J McCauley; J J Fung; H Brown; P Deballi; A Jain; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

10.  Renal transplantation at the University of Pittsburgh: the impact of FK506.

Authors:  R Shapiro; M Jordan; V P Scantlebury; C Vivas; H A Gritsch; A S Rao; M Trucco; A Zeevi; A J Demetris; P Randhawa
Journal:  Clin Transpl       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.